Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS03
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
AS03 is an adjuvant system used in vaccines, particularly for pandemic influenza. It is a stabilized oil-in-water emulsion composed of DL-alpha-tocopherol (vitamin E), squalene, and polysorbate 80. AS03 acts as an immunologic adjuvant by non-specifically stimulating cell-mediated immune responses to enhance the immunogenicity of vaccine antigens, allowing for dose-sparing strategies in vaccine formulation. It has been used in combination with H1N1 and H5N1 influenza antigens in pandemic vaccines such as Arepanrix and Pandemrix. The primary developer and manufacturer is GlaxoSmithKline Biologicals[1][2][3][4][5].
Beyond the preview
Go deeper on AS03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AS03.